AmyP53 is the prototype of a new class of drugs, referred to as chimeric peptides. This innovative approach will make it possible to generate other therapeutic peptides targeting numerous proteinopathies for which there is a strong therapeutic need (diabetes, CJD, ALS, etc.).

AmyPore is a pioneer in the development of inhibitors targeting amyloid pores.